Announced
Synopsis
Merck, a pharmaceutical company, agreed to acquire Caraway Therapeutics, a preclinical biopharmaceutical company, for $610m. “Caraway’s multidisciplinary approach has yielded important progress in evaluating novel mechanisms of modulation of lysosomal function with potential for the treatment of progressive neurodegenerative diseases. We look forward to applying our expertise to build upon this work with the goal of developing much needed disease-modifying therapies for these conditions," George Addona, Merck Senior Vice President.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.